Guggenheim Reiterates Buy on DBV Technologies, Maintains $51 Price Target
3/27/2026
Impact: 70
Healthcare
Guggenheim analyst Yatin Suneja has reiterated a Buy rating on DBV Technologies (NASDAQ: DBVT) and maintained a price target of $51. This endorsement reflects confidence in the company's future performance.
AI summary, not financial advice
Share: